Expert opinion on drug delivery最新文献_第5页

Biomarker-driven and AI-assisted nanomedicine for breast cancer: advancing precision drug delivery from bench to bedside. 生物标志物驱动和人工智能辅助的乳腺癌纳米医学：推进从实验室到床边的精准药物输送。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-06-05 DOI: 10.1080/17425247.2026.2680061

Jaleh Barar, Rais Ansari, Yadollah Omidi

{"title":"Biomarker-driven and AI-assisted nanomedicine for breast cancer: advancing precision drug delivery from bench to bedside.","authors":"Jaleh Barar, Rais Ansari, Yadollah Omidi","doi":"10.1080/17425247.2026.2680061","DOIUrl":"10.1080/17425247.2026.2680061","url":null,"abstract":"Introduction: Breast cancer remains the most prevalent malignancy among women worldwide, with its pronounced molecular heterogeneity demanding therapeutic strategies that transcend conventional systemic chemotherapy toward tumor-selective, molecularly precise interventions. The convergence of biomarker science, engineered nanomedicine, and artificial intelligence (AI) offers a transformative framework for realizing this goal.Areas covered: This review examines how molecular biomarkers (e.g. mucin glycoproteins, human epidermal growth factor receptor 2 (HER2), circulating tumor cells, and circulating tumor DNA) serve dual roles as diagnostic identifiers and active targeting ligands directing engineered nanocarriers. We critically evaluate biomarker-guided nanoplatforms (liposomal, polymeric, metallic, and protein-based architectures), stimuli-responsive drug release strategies, and AI-driven microfluidic manufacturing for scalable, good manufacturing practice-compliant nanoparticle production. Literature was retrieved from PubMed/MEDLINE, Scopus, and Web of Science (2000-2026), supplemented by ClinicalTrials.gov data.Expert opinion: Near-term clinical impact is most realistically achieved through AI-assisted biomarker interpretation and multi-analyte liquid biopsy integration rather than novel nanoformulations, whose translational attrition remains high. Bridging the bench-to-bedside gap requires prospective biomarker-stratified clinical trials, co-developed companion diagnostics, and federated AI architectures as advances that will progressively replace static histological subtype classification with a continuously updated, molecularly individualized treatment paradigm for breast cancer.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1447-1477"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting clinical efficacy of lung gene delivery in people with cystic fibrosis: which in vitro and in vivo models best predict outcomes in human lungs? 预测囊性纤维化患者肺基因传递的临床疗效：哪种体外和体内模型最能预测人肺的结果？

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-06-16 DOI: 10.1080/17425247.2026.2684641

Miftakul Munir, Jeremy Wiyana, Rhiannon B Werder, Neville J Butcher, Rachel Burow, Alexandra McCarron, Qichen Yu, Shafagh A Waters, Lisa M Kaminskas

{"title":"Predicting clinical efficacy of lung gene delivery in people with cystic fibrosis: which in vitro and in vivo models best predict outcomes in human lungs?","authors":"Miftakul Munir, Jeremy Wiyana, Rhiannon B Werder, Neville J Butcher, Rachel Burow, Alexandra McCarron, Qichen Yu, Shafagh A Waters, Lisa M Kaminskas","doi":"10.1080/17425247.2026.2684641","DOIUrl":"10.1080/17425247.2026.2684641","url":null,"abstract":"Introduction: Despite over three-decades of work, no inhalable nucleic acid delivery system for cystic fibrosis (CF) has advanced beyond Phase II due to a lack of congruence between positive outcomes from in vitro and preclinical work, and lung function improvements in people with CF.Areas covered: We review publications covering in vitro and in vivo animal models for CF research from databases including Web of Science and PubMed. Data were used to evaluate the performance of inhaled nucleic acid delivery systems for CF and examine why positive outcomes in these models fail to predict clinical responses.Expert opinion: The field should recalibrate expectations regarding the proportion of epithelial cell correction required for meaningful clinical improvement since the threshold for sustained improvement in lung function in humans may be substantially higher. No single model can predict clinical responses. Translation robustness depends on integrating multiple systems that collectively interrogate delivery, persistence, safety and functional restoration of lung function in clinically meaningful settings. Appropriate in vitro air-liquid interface models that accurately recapitulate the CF airways are important starting points, followed by delivery and functional evaluation in CF animal models that closely resemble human lung physiology and disease phenotype, including pigs and ferrets.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1531-1549"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current trends in semaglutide therapy and strategies to improve its bioavailability. 西马鲁肽治疗的当前趋势和提高其生物利用度的策略。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-06-21 DOI: 10.1080/17425247.2026.2688990

Swasthik Nayak, Akanksha D Dessai, Usha Y Nayak

{"title":"Current trends in semaglutide therapy and strategies to improve its bioavailability.","authors":"Swasthik Nayak, Akanksha D Dessai, Usha Y Nayak","doi":"10.1080/17425247.2026.2688990","DOIUrl":"10.1080/17425247.2026.2688990","url":null,"abstract":"Introduction: A GLP-1 Receptor Agonist, semaglutide, is given in the management of type 2 diabetes mellitus and obese individuals. However, oral semaglutide exerts very low bioavailability due to multiple gastrointestinal and biopharmaceutical barriers. Delivery of oral semaglutide becomes difficult due to instability in GI fluids, degradation through proteolysis by various enzymes, and mucus diffusion limitation; epithelial permeability restricts the oral absorption of the drug, due to which the oral bioavailability of semaglutide is exceedingly low. This review identifies methods that enhance oral bioavailability as well as treatment efficacy of semaglutide.Areas covered: This review provides a broad perspective on the drug and the various formulation strategies that can be developed to increase semaglutide's oral bioavailability, encompassing work on enteric coating, gut-targeted delivery, etc. Databases searched include Scopus, google scholar, PubMed, clinicaltrials.gov etc. This review also discussed and summarized all patents and clinical trials related to semaglutide formulations.Expert opinion: Although various formulation approaches have been explored to improve semaglutide's oral bioavailability, this review proposes novel and promising strategies for gut-targeted delivery and enteric coating. These methods aim to prevent semaglutide from acidic degradation or neutralization in the stomach and from enzymatic degradation, thereby enhancing its intestinal uptake.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1495-1509"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148255183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality by design in advanced anticancer therapeutics: bridging design space, manufacturing, and clinical performance. 先进抗癌治疗药物的设计质量：连接设计空间、制造和临床表现。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-05-20 DOI: 10.1080/17425247.2026.2676799

Maria Beatriz Silva Gonçalves, Paul Hoffmann, Miguel Pereira-Silva, Filipa Mascarenhas-Melo

{"title":"Quality by design in advanced anticancer therapeutics: bridging design space, manufacturing, and clinical performance.","authors":"Maria Beatriz Silva Gonçalves, Paul Hoffmann, Miguel Pereira-Silva, Filipa Mascarenhas-Melo","doi":"10.1080/17425247.2026.2676799","DOIUrl":"10.1080/17425247.2026.2676799","url":null,"abstract":"Introduction: Anticancer therapies increasingly rely on complex formulations and potent compounds with narrow therapeutic windows, making consistent product quality and performance essential. Quality by Design (QbD), supported by ICH Q8-Q10 guidelines, offers a systematic framework integrating formulation design, process understanding, and product quality throughout development, particularly for modern oncology therapeutics. A literature search in PubMed and Google Scholar identified studies published 2016 onwards, prioritizing high-quality (Q1-Q2) journals, yielding 83 references.Area covered: This review discusses how QbD principles guide anticancer drug development, highlighting Quality Target Product Profiles, Critical Quality Attributes, and design space in controlling variability affecting bioavailability, therapeutic index, and clinical outcomes. It examines how Process Analytical Technology, mechanistic modeling, and digital twins support robust manufacturing and scale-up of complex oncology formulations. Selected examples, including imatinib- and paclitaxel-based therapies, illustrate how QbD-informed strategies influence formulation optimization, process robustness, and lifecycle management.Expert opinion: The next phase of oncology drug development will likely depend on integrating QbD with predictive modeling, real-time release testing, and continuous manufacturing to manage targeted therapy complexity. QbD should evolve from a compliance framework into a translational tool linking formulation attributes with in vivo performance, enabling more reliable development and lifecycle management of precision oncology therapeutics.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1381-1402"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oxygen therapy beyond prescription: reframing LTOT as a precision drug delivery system. 超越处方的氧疗：重塑LTOT作为精准给药系统。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-06-05 DOI: 10.1080/17425247.2026.2683628

Rodrigo Torres-Castro, Matías Otto-Yáñez, Alejandro Casas, Xavier Alsina-Restoy, Homero Puppo Gallardo, Roberto Vera-Uribe, Cristina Embid, Diego Rodríguez-Charadía, Isabel Blanco, Jordi Vilaró

{"title":"Oxygen therapy beyond prescription: reframing LTOT as a precision drug delivery system.","authors":"Rodrigo Torres-Castro, Matías Otto-Yáñez, Alejandro Casas, Xavier Alsina-Restoy, Homero Puppo Gallardo, Roberto Vera-Uribe, Cristina Embid, Diego Rodríguez-Charadía, Isabel Blanco, Jordi Vilaró","doi":"10.1080/17425247.2026.2683628","DOIUrl":"10.1080/17425247.2026.2683628","url":null,"abstract":"Introduction: Chronic respiratory diseases are a major global health burden, and oxygen therapy remains a cornerstone treatment for chronic hypoxemia. However, the effectiveness of long-term oxygen therapy (LTOT) depends not only on indication but also on the interaction between device performance, patient physiology, and real-world use. Variability in delivery systems, inadequate titration, and poor adherence often lead to mismatches between prescribed and delivered oxygen doses.Areas covered: This review synthesizes current evidence on LTOT as a drug-delivery system, focusing on device characteristics, delivery performance, and patient-device matching across rest, exertion, and sleep. It examines stationary and portable systems, as well as home high-flow nasal cannula (HFNC). Key challenges such as pulse-dose variability, device limitations, adherence, and safety are addressed. Evidence from clinical trials, physiological studies, registries, and guidelines is integrated to show how delivery systems and patient factors influence effectiveness.Expert opinion: LTOT should be reframed as a precision drug delivery system rather than a simple flow-based prescription. Device-specific titration, confirmation of adequate oxygenation with the prescribed device under the intended conditions of use, and individualized matching are essential. Future strategies should prioritize objective monitoring, advanced technologies, and scalable education to reduce the gap between prescription and real-world effectiveness.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1551-1569"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148102278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioconjugates for breast cancer theranostics: improving target selectivity and treatment efficacy. 生物偶联物用于乳腺癌治疗：提高靶点选择性和治疗效果。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-06-10 DOI: 10.1080/17425247.2026.2682898

Neha Jain, Shreya Kaul, Rupali Verma, Aruna Sharma, Manisha Pandey, Amit Chaudhary, Upendra Nagaich

{"title":"Bioconjugates for breast cancer theranostics: improving target selectivity and treatment efficacy.","authors":"Neha Jain, Shreya Kaul, Rupali Verma, Aruna Sharma, Manisha Pandey, Amit Chaudhary, Upendra Nagaich","doi":"10.1080/17425247.2026.2682898","DOIUrl":"10.1080/17425247.2026.2682898","url":null,"abstract":"Introduction: Breast cancer is the most common cancer diagnosed globally, with various levels of heterogeneity. The current treatment strategy for breast cancer includes surgery, chemotherapy, radiation, hormone, targeted, and immunotherapy. These strategies are combined according to the stage, patient factors, and molecular subtype of breast cancer to enhance survival and diminish the recurrence of cases. Several adverse effects and challenges are associated with these therapies, which render the patient uncomfortable and non-compliant.Areas covered: Bioconjugate-based therapy is one of the advanced therapies emerging to diagnose and treat breast cancer, in which conjugation is done between various molecules, such as monoclonal antibodies and cytotoxic drugs, radionuclides, enzymes, polymers, ligands, and nanoparticles, using linkers. This review aims to critically discuss bioconjugate's recent research advancements in breast cancer theranostics, highlighting their strengths and gaps toward clinical translation, along with patents and clinical trials. PubMed, Scopus, and Google Scholar were used to search the literature in the last five years (2021 to present).Expert opinion: The outcomes of the findings are promising; however, more studies need to be done to establish the mechanistic pathway, long-term toxicity, safety, efficacy, and stability of the bioconjugates for breast cancer to move toward clinical settings.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1421-1445"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148058964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of targeted drug delivery systems specific for fibroblast growth factor receptors and their co-receptors. 针对成纤维细胞生长因子受体及其共受体的靶向药物递送系统综述。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-05-19 DOI: 10.1080/17425247.2026.2674687

Krzysztof Ciura, Natalia Porębska, Łukasz Opaliński

{"title":"An overview of targeted drug delivery systems specific for fibroblast growth factor receptors and their co-receptors.","authors":"Krzysztof Ciura, Natalia Porębska, Łukasz Opaliński","doi":"10.1080/17425247.2026.2674687","DOIUrl":"10.1080/17425247.2026.2674687","url":null,"abstract":"Introduction: The growing number of patients diagnosed with cancer highlights the need for development of new therapeutic strategies. Targeted therapies, especially DDSs, have attracted increasing interest in recent years, mostly because of selective delivery of cytotoxic agents to cancer cells and overcoming some cancer resistance mechanisms.Areas covered: FGFRs and their co-receptors, especially HSPGs, represent attractive molecular targets for DDSs due to their dysregulation across multiple cancer types. To date, nearly 60 DDSs targeting FGFRs and/or HSPGs have been reported in the literature, spanning a wide range of cytotoxic efficacy and developmental stages. Several of these candidates have entered Phase I of clinical trials, but none has yet received FDA approval. In this review, we provide a comprehensive overview of DDSs targeting FGFRs and HSPGs in cancer. Literature was identified through PubMed up to March 2026, with selection focused on studies related to targeted drug delivery systems specific for fibroblast growth factor receptors and their co-receptors.Expert opinion: FGFR/HSPG-targeted DDSs show potential mainly within targeted therapies, but clinical translation is limited by target expression in normal tissues and insufficient efficacy of current ADCs. Future progress depends on better target validation, co-expression analysis, and development of multivalent or PDC-based strategies integrated with molecular patient stratification.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1403-1420"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147936518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of in vitro blood-brain barrier models in central nervous system new drug development: methodological challenges and translational perspectives. 体外血脑屏障模型在中枢神经系统新药开发中的评价：方法学挑战和翻译观点。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-06-02 DOI: 10.1080/17425247.2026.2676068

Chang-Uk Lee, Dan Bi Park, Eunyoung Lee, Seung Joon Kim, Yu-Jeong Seong, Yongki Hwang, Hyobin Won, Soo Bin Choi, Bosung Ku, Dong Woo Lee, Sang-Yun Lee

{"title":"Evaluation of in vitro blood-brain barrier models in central nervous system new drug development: methodological challenges and translational perspectives.","authors":"Chang-Uk Lee, Dan Bi Park, Eunyoung Lee, Seung Joon Kim, Yu-Jeong Seong, Yongki Hwang, Hyobin Won, Soo Bin Choi, Bosung Ku, Dong Woo Lee, Sang-Yun Lee","doi":"10.1080/17425247.2026.2676068","DOIUrl":"10.1080/17425247.2026.2676068","url":null,"abstract":"Introduction: Central nervous system (CNS) drug development remains challenging because effective delivery across the blood-brain barrier (BBB) is difficult to predict preclinically. In vitro BBB models are increasingly used to evaluate barrier properties and drug transport, but platform variability and limited standardization hinder consistent interpretation and translational use.Areas covered: This review summarizes major cell-based in vitro BBB models for CNS drug development, focusing on static, dynamic, microfluidic, induced pluripotent stem cell-derived, and three-dimensional (3D) BBB platforms. Emphasis is placed on model applicability for permeability assessment, transporter activity, exposure kinetics, spatial distribution, and translational prediction. Relevant literature was searched using PubMed, Web of Science, and Google Scholar up to 2025.Expert opinion: Although in vitro BBB models have advanced substantially, no single system fully reproduces the complexity of the in vivo BBB. The major limitation is persistent inconsistency across models, which complicates interpretation and limits confidence in their translational application. Static models are practical but provide only partial representation of BBB function, whereas stem cell-based and microfluidic platforms offer greater physiological relevance but face reproducibility and scalability challenges. Future progress should prioritize context-of-use-driven model selection, tiered validation, and harmonized reporting to support reliable decision-making in CNS drug development.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1479-1493"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing transdermal drug delivery: integration of microneedle technology and iontophoresis for enhanced therapeutic outcomes. 推进经皮给药：微针技术和离子透入的整合以提高治疗效果。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-05-05 DOI: 10.1080/17425247.2026.2667834

Meheli Ghosh, Amruta A Dandekar, Ajay K Banga, Ashana Puri

{"title":"Advancing transdermal drug delivery: integration of microneedle technology and iontophoresis for enhanced therapeutic outcomes.","authors":"Meheli Ghosh, Amruta A Dandekar, Ajay K Banga, Ashana Puri","doi":"10.1080/17425247.2026.2667834","DOIUrl":"10.1080/17425247.2026.2667834","url":null,"abstract":"Introduction: Integrated microneedle-iontophoresis (MN-ITP) systems are emerging as a promising approach to improve transdermal drug delivery. These work by dual effect, such as mechanical disruption of the stratum corneum along with electrically driven transport. This approach has gained increasing attention for both small molecules and macromolecules, offering the possibility of controlled, minimally invasive administration with improved pharmacokinetic outcomes compared with conventional methods.Areas covered: This review highlights MN-ITP strategies for transdermal delivery, based on a targeted search of major databases, patents, and FDA guidance (1984-2026), emphasizing therapeutic applications since 2015. Different MN-ITP device designs investigated for small molecules as well as larger therapeutics, such as peptides, proteins, and vaccines have been discussed. The review focuses on how device design, drug properties, and delivery performance influence outcomes, and compares integrated simultaneous systems with sequential MN-ITP approaches.Expert opinion/commentary: Current evidence indicates that integrated MN-ITP systems can enhance transdermal delivery, though outcomes depend on drug properties, loading strategies, and electrical parameters. Combined systems often act complementarily rather than uniformly superior, highlighting the need for rational, drug-specific design. Future work should focus on wearable and closed-loop platforms, optimized current density and MN architecture, and clinical translation.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1511-1530"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor: 'Saving money but costing lives: the lack of integrated dose counters on pressurised metered dose inhalers'. 给编辑的信：“省钱但牺牲生命：在加压计量吸入器上缺乏综合剂量计数器”。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-07-01 DOI: 10.1080/17425247.2026.2694894

Roni Y Kraut, Mathew Katz, Oksana Babenko

引用次数: 0